| Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med |
NCT03704246: Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors |
|
|
| Active, not recruiting | 2 | 123 | RoW | Anti-PD-1 monoclonal antibody, HX008 | Taizhou Hanzhong biomedical co. LTD | Advanced Solid Tumor | 12/19 | 03/21 | | |
| Active, not recruiting | 2 | 119 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Melanoma | 08/20 | 11/21 | | |
NCT04741165: Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 72 | RoW | HX008, Bevacizumab, AVASTIN®, Lenvatinib, LENVIMA® | Taizhou Hanzhong biomedical co. LTD | Hepatocellular Carcinoma | 04/22 | 10/22 | | |
NCT04574817: Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) |
|
|
| Not yet recruiting | 2 | 66 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Anaplastic Thyroid Cancer | 05/22 | 05/23 | | |
| Recruiting | 2 | 37 | RoW | HX008，Niraparib, HX008，Niraparib，Trastuzumab, HX008，Niraparib，Pyrrolitinib | Fudan University | Treatment Efficacy | 11/22 | 12/22 | | |
NCT04738630: Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 110 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Bladder Cancer | 12/22 | 12/23 | | |
NCT06129955: Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 47 | RoW | Pucotenlimab Combined With Lenvatinib | Sun Yat-sen University | Renal Cell Carcinoma | 12/25 | 12/25 | | |
CCGLC-012, NCT06192784: Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 36 | RoW | DEB-TACE, drug eluting beads-transcatheter arterial chemoembolization, Lenvatinib plus pucotenlimab, levima plus pucotenlimab | Tongji Hospital, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC) | Cholangiocarcinoma Non-resectable | 01/25 | 06/25 | | |
CCGLC-013, NCT06192797: Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 36 | RoW | HAIC, hepatic arterial infusion chemotherapy of GEMOX, Lenvatinib plus pucotenlimab, levima plus pucotenlimab | Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer | Cholangiocarcinoma Non-resectable | 12/25 | 06/26 | | |
NCT04750382: A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer |
|
|
| Active, not recruiting | 1/2 | 31 | RoW | HX008+Cisplatin+Gemcitabine | Taizhou Hanzhong biomedical co. LTD | Triple-negative Breast Cancer | 12/20 | 12/21 | | |
| Recruiting | 1/2 | 300 | RoW | OH2 injection, with or without irinotecan or HX008 | Binhui Biopharmaceutical Co., Ltd. | Solid Tumor, Gastrointestinal Cancer | 08/24 | 08/24 | | |
NCT04616443: OH2 Injection in Combination With HX008 for Melanoma. |
|
|
| Recruiting | 1/2 | 60 | RoW | OH2 injection, HX008 injection | Binhui Biopharmaceutical Co., Ltd. | Melanoma | 11/23 | 11/23 | | |
NCT05338957: A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. |
|
|
| Recruiting | 1/2 | 30 | RoW | MRG002+HX008 | Shanghai Miracogen Inc. | Advanced Malignant Solid Tumors | 06/24 | 12/24 | | |
NCT06456892: Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen |
|
|
| Recruiting | 1/2 | 82 | RoW | Pucotenlimab | Sun Yat-sen University | Rhabdomyosarcoma, Pediatric Cancer | 06/26 | 12/26 | | |
NCT05688605: A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 18 | RoW | MRG003+HX008 | Shanghai Miracogen Inc. | Advanced Solid Tumors | 05/25 | 07/25 | | |
